Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysisAndrea Casadei‐Gardini, Alessandro Cucchetti, Mario Scartozzi et al.|Liver International|2021Cited by 60
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Cancers|2020Cited by 54
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control studyMargherita Rimini, Andrea Casadei‐Gardini, Shigeo Shimose et al.|Hepatology Research|2021Cited by 46
Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteriaHironori Ochi, Kouji Joko, Atsushi Hiraoka et al.|Journal of Gastroenterology|2020Cited by 45
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT StudyAndrea Casadei‐Gardini, Stefano Cascinu, Margherita Rimini et al.|Liver Cancer|2022Cited by 43